Key statistics
As of last trade, BioMarin Pharmaceutical Inc (B1MR34:SAO) traded at 160.17, 15.10% above the 52 week low of 139.16 set on Nov 06, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 160.17 |
|---|---|
| High | 160.17 |
| Low | 160.17 |
| Bid | 155.04 |
| Offer | 159.52 |
| Previous close | 160.17 |
| Average volume | 1.65k |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Mar 03 2026 14:29 GMT.
More ▼
Press releases
- U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
- BioMarin to Participate in Four Upcoming Investor Conferences in March
- BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
- Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
- BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
- BioMarin Announces Closing of Private Offering of Senior Notes
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
- BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer
- BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
More ▼
